skin microbiome support, modulation

The portfolio indicates a move away from broad-spectrum actives like zinc pyrithione toward the use of native human commensals to regulate the scalp ecosystem. Recent patents published in late 2024 and 2025 disclose the isolation and application of specific strains, including Staphylococcus capitis CCSMS0308, Propionibacterium acnes CCSMS0630, and Bifidobacterium longum subsp. infantis WZA-BI09, to treat hair loss and dandruff. This technical trajectory suggests a strategy of competitive exclusion, where proprietary bacterial agents or their fermentation supernatants are used to displace pathogens rather than simply sterilizing the skin surface.

The portfolio is heavily concentrated in scalp-specific biological modulation, with Cosmetic & Scalp Formulation accounting for 63.1% of the 1,665 documents in the corpus. The technical record shows a decisive shift away from broad antimicrobial suppression toward the use of native human strains, such as Staphylococcus capitis (CCSMS0308) and Propionibacterium acnes (CCSMS0630), both published in late 2024 for their anti-inflammatory and antioxidant properties;. This focus on specific bacterial agents suggests a strategic decision to build defensive moats around proprietary microbial strains rather than generic chemical actives.

A significant divergence exists between high-resolution clinical modeling and the actual patent record. While the Analytical Methods & Modeling area contains 33 items of high-visibility coverage in journals like Nature and the European Medical Journal regarding bio-integrated skin models, it contains zero new inventions. This suggests that while the "skin-mind-microbiome" axis is a dominant research narrative, it has not yet been translated into a proprietary moat for diagnostic tools or predictive algorithms.

While market discourse emphasizes "probiotic" benefits, the technical record shows a concentration in non-viable bacterial derivatives. Inventions published between 2024 and 2025, such as KR102680493B1 and FR3125717B1, focus on lactic acid bacteria hydrolysates and Bifidobacterium species lysates rather than live cultures. These compositions are frequently combined with antioxidants and yeast extracts to restore flora balance, suggesting that the company is prioritizing manufacturing scalability and shelf stability over the complex delivery requirements of live microorganisms.

While the commercial narrative emphasizes "microbiome-friendly" ingredients, the technical weight sits firmly in non-viable bacterial derivatives. In July 2024, the company published work on lactic acid bacteria hydrolyzates for hair loss, and late 2025 filings detail Bifidobacterium longum postbiotics for scalp protection.

Despite the commercial narrative of "live microbiome" care, the technical record shows a heavy reliance on non-viable fermentation filtrates and bacterial lysates to bypass stabilization and regulatory hurdles. The dominant technical cluster, accounting for 47.0% of the Cosmetic & Scalp Formulation area, is centered on fermentation products rather than live cultures. Recent filings in 2024 and 2025 specifically utilize Lactobacillus and Bifidobacterium lysates combined with antioxidants to restore flora balance without the manufacturing complexity of live strain maintenance,.

The portfolio is evolving toward high-precision delivery mechanisms that penetrate the skin barrier to deliver active ingredients. A 2025 publication describes a biodegradable microneedle matrix composed of chitosan and silk fibroin for hair growth, while earlier 2022 filings explored nanoparticle composite hydrogels loaded with stem cell factor nanoparticles. This shift suggests that the entity is positioning itself to compete in a high-margin "clinical-cosmetic" tier where delivery efficiency is as critical as the active ingredient itself.